Results 111 to 120 of about 22,142 (188)

Real-world toxicity and discontinuation risk in ibrutinib therapy: a retrospective cohort study. [PDF]

Front Med (Lausanne)
Alyamani WM, Khobrani A, Alenazy FO, Alzahrani YA, Harbi MH.   +4 more
europepmc   +1 more source

Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

, 2018
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression.
Barr, Paul M., Li, Jianyong, Stevens, Don A., Grosicki, Sebastian, Gaidano, Gianluca, Robak, Tadeusz, Maslyak, Zvenyslava, Bairey, Osnat, Burger, Jan A., Hillmen, Peter, McCarthy, Helen, Owen, Carolyn, Janssens, Ann, Tedeschi, Alessandra, Quach, Hang, Simpson, David, Coutre, Steven, Ghia, Paolo, Bartlett, Nancy L., Devereux, Stephen   +19 more
core  

Comparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

J Cell Mol Med
Xu F, Zou X, Yang Y, Zhou K, Huang W.
europepmc   +1 more source

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives. [PDF]

Cancers (Basel)
Robak T, Wolska-Washer A, Robak P.
europepmc   +1 more source

Integrating Network Pharmacology and Experimental Validation Reveals EGFR/PI3K/Akt Axis Mediates Ibrutinib-Induced Cardiotoxicity. [PDF]

Dose Response
Guan Y, Mei J, He Y, Lu M, Cheng B, Zhang X.   +5 more
europepmc   +1 more source

Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States. [PDF]

Future Oncol
Brown JR, Munir T, Lipsky AH, Challagulla S, Campbell D, Yang K, Fu Q, Aldairy W, Williams R, Tam CS.   +9 more
europepmc   +1 more source

Generational safety profiles of BTK inhibitors: adverse reaction signals and real-world evidence from the FAERS database. [PDF]

Front Med (Lausanne)
Tu J, Wang Z, Zhang J, Xu H, Li Y, Zhang L, Gong J, Zhao L.   +7 more
europepmc   +1 more source

Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR-T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages. [PDF]

J Cell Mol Med
Qi Y, Fan X, Wang J, Li X, Mu J, Cui R, Deng Q.   +6 more
europepmc   +1 more source

A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax. [PDF]

Hemasphere
Hermansen JU, Kong W, Brodersen AM, Yin Y, Urban A, Rein ID, He L, Agius R, Teglgaard RS, Rousu J, Brieghel C, Kersting S, Levin MD, Tran HTT, Mattsson M, Ranti J, Veldhuis GJ, da Cunha-Bang C, Mous R, Dubois J, Kater AP, Enserink JM, Niemann CU, Aittokallio T, Skånland SS.   +24 more
europepmc   +1 more source

Drug Safety and Polypharmacy Signals in Ibrutinib-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Age- and Sex-Specific FAERS Analysis of CYP3A Modifier and Antithrombotic Co-Exposure. [PDF]

J Clin Med
Shivarov V.
europepmc   +1 more source